Higher Efficacy of Urinary Bone Resorption Marker Measurements in Assessing Response to Treatment for Osteoporosis in Postmenopausal Women

Abe, Yoshihiro; Ishikawa, Hitoshi; Fukao, Akira
January 2008
Tohoku Journal of Experimental Medicine;Jan2008, Vol. 214 Issue 1, p51
Academic Journal
Osteoporosis has reached epidemic proportions. This situation has stimulated the development of biochemical markers to assist in assessing osteoporotic risk and monitoring treatment efficacy. Biochemical markers for assessing the level of bone resorption have been developed during the last few decades. One of the most widely used bone resorption markers is cross-linked N-terminal telopeptides (NTX). Measurements of urinary and serum NTX provide indications of the level of bone resorption during osteoporosis treatment. However, it remains unclear whether urinary or serum NTX measurements show better efficacy for assessing osteoporosis treatment effects during the early phase of treatment. Therefore, the primary aim of the present study was to compare the efficacies of urinary and serum NTX measurements for assessing the level of bone resorption during the early stage of osteoporosis treatment. We enrolled 43 postmenopausal Japanese women in an open-label randomized placebo-controlled trial. Overall, 21 women in the osteoporosis treatment group and 19 women in the placebo group completed the study. There was a significant reduction in urinary NTX in the treatment group, which was detectable as early as 4 weeks and maintained until 16 weeks, compared with the placebo group. On the other hand, serum NTX did not show a significant reduction in the treatment group compared with the placebo group until 16 weeks. These results indicate that urinary NTX measurements are more sensitive and show higher efficacy than serum NTX measurements for assessing treatment effect during the early phase of osteoporosis treatment in postmenopausal women.


Related Articles

  • INFLUENCE OF YEARS SINCE MENOPAUSE ON BONE MINERAL METABOLISM IN SOUTH INDIAN WOMEN. Suresh, M.; Naidu, Dhananjaya M. // Indian Journal of Medical Sciences;May2006, Vol. 60 Issue 5, p190 

    BACKGROUND: Although an increase of bone turnover has been documented at the time of menopause, the subsequent abnormalities of bone resorption and formation in the elder women have not been investigated. AIM: To assess bone turnover among different YSM (years since menopause) groups of...

  • Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone Density and Turnover in Postmenopausal Women with Osteoporosis: Results of FACTS1 1 Fosamax Actonel Comparison Trials. -International. Reid, David M.; Hosking, David; Kendler, David; Brandi, Maria L.; Wark, John D.; Weryha, Georges; Marques-Neto, João F.; Gaines, Keavy A.; Verbruggen, Nadia; Melton, Mary E. // Clinical Drug Investigation;2006, Vol. 26 Issue 2, p63 

    Background: The objective of the study was to evaluate the effects of alendronic acid once weekly relative to risedronic acid once weekly on bone mineral density (BMD), markers of bone turnover and tolerability in the treatment of osteoporosis in postmenopausal women. Methods: This was a...

  • HORIZON: Yearly infusion of zoledronic acid reduces risk of fracture in postmenopausal women with osteoporosis.  // Formulary;Aug2007, Vol. 42 Issue 8, p488 

    The article focuses on the therapeutic use of zoledronic acid in reducing fracture risk in postmenopausal women with osteoporosis. Study shows that a single, annual intravenous (IV) zoledronic acid infusion decreases the risk of vertebral fracture by 70 percent and the risk of hip fracture by 41...

  • Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis. Frampton, James E.; Perry, Caroline M. // Drugs;2008, Vol. 68 Issue 18, p2683 

    Abstract Ibandronate (ibandronic acid; Bonviva®, Boniva®), a nitrogen-containing bisphosphonate available in once-monthly oral and quarterly intravenous formulations for intermittent administration, has been approved for the treatment of osteoporosis in postmenopausal women in the EU, the...

  • Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy. Stoch, S. A.; Wagner, J. A. // Clinical Pharmacology & Therapeutics;Jan2008, Vol. 83 Issue 1, p172 

    Osteoporosis is characterized by low bone mass with skeletal fragility and an increased risk of fracture. This bone loss is brought about by an imbalance between bone resorption and formation. Cathepsin K is the most abundant cysteine protease expressed in the osteoclast and is believed to be...

  • Yearly and Twice Yearly Pharmacotherapy in Postmenopausal Osteoporosis. Tandon, Vishal R.; Mir, Shakeel Ahmad; Singh, Zorawar; Sharma, Rajesh // JK Science;Jan-Mar2009, Vol. 11 Issue 1, p47 

    The article discusses the importance of yearly and twice yearly pharmacology in treating postmenopausal osteoporosis. It examines the efficacy of Zoledronic acid and Denosumab in treating this osteoporosis. It notes that 5 milligram of intravenous infusion of Zoledronic acid can lower bone...

  • Delphinidin, One of the Major Anthocyanidins, Prevents Bone Loss through the Inhibition of Excessive Osteoclastogenesis in Osteoporosis Model Mice. Moriwaki, Sawako; Suzuki, Keiko; Muramatsu, Masashi; Nomura, Atsushi; Inoue, Fumihide; Into, Takeshi; Yoshiko, Yuji; Niida, Shumpei // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Anthocyanins, one of the flavonoid subtypes, are a large family of water-soluble phytopigments and have a wide range of health-promoting benefits. Recently, an anthocyanin-rich compound from blueberries was reported to possess protective property against bone loss in ovariectomized (OVX) animal...

  • bone up on osteoporosis. Kane, Emily // Better Nutrition;Dec2007, Vol. 69 Issue 12, p30 

    The article presents questions and answers related to health including the treatment of a 50-year-old woman suffering from osteoporosis and the best way to use zinc lozenges for quick cold relief.

  • Osteoporosis is common in Greenland and treatment is scarce. Jakobsen, Anna; Laurberg, Peter; Andersen, Stig // Circumpolar Health Supplements;2013 Supplement 1, Vol. 72, p332 

    The article focuses on a study which described the occurrence of risk factors for osteoporosis among populations in Nuuk. It found that factors known to increase the risk of osteoporosis were common among populations in Nuuk and age was a dominant risk factor for fragility fractures. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics